Stock 4563 ANGES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News AnGes, Inc.

Equities

4563

JP3127700007

Delayed Japan Exchange
Other stock markets
 07:00:00 03/07/2024 BST 		5-day change 1st Jan Change
44 JPY 0.00% Intraday chart for AnGes, Inc. -2.22% -38.89%
01-19 Eiger BioPharmaceuticals Gets Marketing Approval for Treatment of Ultra-Rare Genetic Disease MT
01-18 Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
AnGes : Strategic Change in Product Development -Collategene (HGF gene therapy product)
PU
AnGes : Notice Concerning Supply Agreement for "Zokinvy"
PU
AnGes : Tie2 receptor agonist (AV 001), co development product, received fast track designation from the U.S. FDA
PU
AnGes : Notice of Launch Date for Zokinvy (Orphan Drug) for the Treatment of Progeria
PU
AnGes : Consolidated Financial Report for the First Quarter 2024
PU
AnGes : Notice Regarding the Decision to Sell the ZOKINVY Business of Eiger BioPharmaceuticals, Inc.
PU
AnGes : Notice on the NHI Drug Price Standard Listing and Launch Schedule of Zokinvy for the Treatment of Progeria
PU
AnGes : Notice Regarding Eiger BioPharmaceuticals, Inc.
PU
AnGes : Notice of Business Restructuring at Consolidated Subsidiary
PU
AnGes : Notice of Conclusion of License Agreement and Revision of Consolidated Financial Results Forecast for FY2024
PU
Eiger and Partner, AnGes, Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan
AQ
Eiger BioPharmaceuticals Gets Marketing Approval for Treatment of Ultra-Rare Genetic Disease
MT
Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan
CI
Vasomune Therapeutics, Inc. and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study
CI
AnGes : Consolidated Financial Report for the Third Quater 2023
PU
AnGes : Notice Regarding the Start of Administration of NF-κB Decoy Oligo DNA for the Treatment of Chronic Intervertebral Disc Lumbago in a Phase II Clinical Trial in Japan
PU
AnGes : Consolidated Financial Report Q2 2023
PU
AnGes : Consolidated Financial Report for the Second Quater 2023
PU
Tupperware Brands Corporation : Plastic is fantastic
Our Logo
AnGes : Clinical Research Laboratory has now established "Genetic Testing" technology and aims to begin accepting orders for "genetic testing" in winter 2023
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4563 Stock
  4. News AnGes, Inc.